Infection prevention and control in cystic fibrosis

Current Opinion in Infectious Diseases

Volumn 24, Issue 4, 2011, Pages 390-395

  Saiman, Lisa ^a,b,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c 650 West 168th Street PH 4 ^*  (United States)

Author keywords

adherence to infection control; droplet nuclei; endemic Pseudomonas aeruginosa; methicillin resistant Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT;

ACHROMOBACTER XYLOSOXIDANS; AMBIENT AIR; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM CONTAMINATION; BURKHOLDERIA CENOCEPACIA; CYSTIC FIBROSIS; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; REVIEW; SOCIAL NETWORK; STENOTROPHOMONAS MALTOPHILIA; TREATMENT DURATION;

CYSTIC FIBROSIS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

EID: 79960204922     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834748ff     Document Type: Review

References (19)

1. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003; 24:S6-S52. (Pubitemid 36617275)
2. Doe SJ, McSorley A, Isalska B, et al. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros 2010; 9:104-109.
3. Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 303:2386-2392.
4. Stone A, Quittell L, Zhou J, et al. Staphylococcus aureus nasal colonization among pediatric cystic fibrosis patients and their household contacts. Pediatr Infect Dis J 2009; 28:895-899.
5. Cafiso V, Bertuccio T, Spina D, et al. Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2010; 29:1277-1285.
6. Rolain JM, Francois P, Hernandez D, et al. Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage. Biol Direct 2009; 4:1-15.
7. Hill RL, Kearns AM, Nash J, et al. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J Antimicrob Chemother 2010; 65:442-445.
8. Aaron SD, Vandemheen KL, Ramotar K, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 2010; 304:2145-2153.
9. Cheng K, Smyth RL, Govan JR, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996; 348: 639-642. (Pubitemid 26293808)
10. Winstanley C, Langille MG, Fothergill JL, et al. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool epidemic strain of Pseudomonas aeruginosa. Genome Res 2009; 19:12-23.
11. Tingpej P, Elkins M, Rose B, et al. Clinical profile of adult cystic fibrosis patients with frequent epidemic clones of Pseudomonas aeruginosa. Respirology 2010; 15:923-929.
12. Jones AM, Dodd ME, Morris J, et al. Clinical outcome for cystic fibrosis patients infected with transmissible Pseudomonas aeruginosa: an 8-year prospective study. Chest 2010; 137:1405-1409.
13. Lambiase A, Catania MR, Del Pezzo M, et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2011 [Epub ahead of print].
14. 2007Guidelines for isolation precautions: Preventing transmission of infectious agents in healthcare settings. Centers for Disease Control and Prevention, 2007. http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf (accessed March 2011).
15. Clifton IJ, Peckham DG. Defining routes of airborne transmission of Pseudomonas aeruginosa in people with cystic fibrosis. Expert Rev Respir Med 2010; 4:519-529.
16. Wainwright CE, France MW, O'Rourke P, et al. Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis. Thorax 2009; 64:926-931.
17. Festini F, Taccetti G, Galici V, et al. A 1-m distance is not safe for children with cystic fibrosis at risk for cross-infection with Pseudomonas aeruginosa. Am J Infect Control 2010; 38:244-245.
18. Zuckerman JB, Zuaro DE, Prato BS, et al. Bacterial contamination of cystic fibrosis clinics. J Cyst Fibros 2009; 8:186-192.
19. Masterson TL, Wildman BG, Newberry BH, Omlor GJ. Impact of age and gender on adherence to infection control guidelines and medical regimens in cystic fibrosis. Pediatr Pulmonol 2010 [Epub ahead of print].